Global In-Situ Hybridization Market Is Expanding Owing To Growing Prevalence Of Cancer And Increasing Awareness Associated With Cancer Therapeutics

 

In-Situ Hybridization

Overview:

In-Situ Hybridization is a technique that allows the detection of specific nucleotide sequences within cells or morphologically preserved tissue sections. The probe used in the hybridization can be labeled with either radio- or fluorescent tags. The detectable signal can be visualized by autoradiography, fluorescence microscopy or immunohistochemistry. The principle of in situ hybridization is based on the ability of complementary DNA- or RNA-probes to specifically anneal to each other and form a hybrid. Both isotopic and nonisotopic methods can be used. Several in situ hybridization techniques have been developed for the detection of specific sequences within intact cells or chromosomal regions in fixed tissues. The most popular and widely used is the FISH technique, which uses labeled DNA- or RNA-probes that specifically bind to matching chromosomal sequences and then emit a fluorescent signal upon hybridization. Other in situ hybridization techniques include COMBO-FISH, telomere FISH, Quantitative-FISH and PNA-FISH.

Market Dynamics:

Growing collaborations among key players are estimated to augment growth of the global In-Situ Hybridization Market during the forecast period. For instance, Capio Biosciences and BioView collaborated in July 2021, for developing a platform for collecting Circulating Tumor Cells from whole blood. Integration of technologies from both the companies will advance the CTC Liquid Biopsy downstream analysis. Moreover, lack of skilled professionals and easy availability of other methods is anticipated to restrain growth of the global in-situ hybridization market during the forecast period.

Impact of COVID-19:

COVID-19 affected millions of individuals and several people lost their lives. The pandemic affected many countries globally. The pandemic had a significant impact on the in situ hybridization market. As there was no cure for COVID-19, immense research activities were being conducted to develop a treatments, or drug or a vaccine for the disease. This led to use of several molecular techniques. Several pharmaceutical companies were conducting researches for developing these drugs. This led to increase in demand for in-situ hybridization market. Thus, the pandemic augmented the growth of the global In-Situ Hybridization Market during the pandemic.

Key Takeaways:

The global In-Situ Hybridization Market is expected to witness robust growth, exhibiting CAGR of 6.98 % over the forecast period, due to rising product launches. For instance, a high-speed in situ hybridization staining platform was launched by Leica Biosystems launched in May 2022. The universal access will enable technicians in loading slides in any combination at any time with any reagent.

North America is anticipated to witness robust growth in the global In-Situ Hybridization Market during the forecast period, due to rising prevalence of infectious diseases and cancer.

Key players active in the global In-Situ Hybridization Market are Bio SB Inc., Abnova Corporation, Creative Bioarray, Agilent Technologies Inc., Zytomed Systems GmbH, F. Hoffmann-La Roche Ltd, Biogenex Laboratories, Biocare Medical LLC., Thermo Fisher Scientific Inc., and Genemed Biotechnologies Inc.